King's College London

Research portal

The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study

Research output: Contribution to journalArticle

Standard

The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma : a multi-centre study. / Ramsenthaler, Christina; Osborne, Thomas R; Gao, Wei; Siegert, Richard J; Edmonds, Polly M; Schey, Stephen A; Higginson, Irene J.

In: BMC Cancer, Vol. 16, 07.07.2016, p. 427.

Research output: Contribution to journalArticle

Harvard

Ramsenthaler, C, Osborne, TR, Gao, W, Siegert, RJ, Edmonds, PM, Schey, SA & Higginson, IJ 2016, 'The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study', BMC Cancer, vol. 16, pp. 427. https://doi.org/10.1186/s12885-016-2410-2

APA

Ramsenthaler, C., Osborne, T. R., Gao, W., Siegert, R. J., Edmonds, P. M., Schey, S. A., & Higginson, I. J. (2016). The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer, 16, 427. https://doi.org/10.1186/s12885-016-2410-2

Vancouver

Ramsenthaler C, Osborne TR, Gao W, Siegert RJ, Edmonds PM, Schey SA et al. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer. 2016 Jul 7;16:427. https://doi.org/10.1186/s12885-016-2410-2

Author

Ramsenthaler, Christina ; Osborne, Thomas R ; Gao, Wei ; Siegert, Richard J ; Edmonds, Polly M ; Schey, Stephen A ; Higginson, Irene J. / The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma : a multi-centre study. In: BMC Cancer. 2016 ; Vol. 16. pp. 427.

Bibtex Download

@article{a7f83e380f47491485046eba92f4d852,
title = "The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study",
abstract = "BACKGROUND: Multiple myeloma, the second most common haematological cancer, remains incurable. Its incidence is rising due to population ageing. Despite the impact of the disease and its treatment, not much is known on who is most in need of supportive and palliative care. This study aimed to (a) assess symptom severity, palliative care concerns and health-related quality of life (HRQOL) in patients with multiple myeloma, and (b) to determine which factors are associated with a lower quality of life. We further wanted to know (c) whether general symptom level has a stronger influence on HRQOL than disease characteristics.METHODS: This multi-centre cross-sectional study sampled two cohorts of patients with multiple myeloma from 18 haematological cancer centres in the UK. The Myeloma Patient Outcome Scale (MyPOS) was used to measure symptoms and concerns. Measures of quality of life included the EORTC QLQ-C30, its myeloma module and the EuroQoL EQ-5D. Data were collected on socio-demographic, disease and treatment characteristics and phase of illness. Point prevalence of symptoms and concerns was determined. Multiple regression models quantified relationships between independent factors and the MyPOS, EORTC global quality of life item and EQ5D Index.RESULTS: Five-hundred-fifty-seven patients, on average 3.5 years (SD: 3.4) post-diagnosis, were recruited. 18.2 {\%} had newly diagnosed disease, 47.9 {\%} were in a treatment-free interval and 32.7 {\%} had relapsed/progressive disease phase. Patients reported a mean of 7.2 symptoms (SD: 3.3) out of 15 potential symptoms. The most common symptoms were pain (72 {\%}), fatigue (88 {\%}) and breathlessness (61 {\%}). Those with relapsed/progressive disease reported the highest mean number of symptoms and the highest overall palliative care concerns (F = 9.56, p < 0.001). Factors associated with high palliative care concerns were a general high symptom level, presence of pain, anxiety, low physical function, younger age, and being in the advanced stages of disease.CONCLUSION: Patients with multiple myeloma have a high symptom burden and low HRQOL, in the advanced and the earlier stages of disease. Identification of patients in need of supportive care should focus on assessing patient-reported outcomes such as symptoms and functioning regularly in clinical practice, complementary to traditional biomedical markers.",
author = "Christina Ramsenthaler and Osborne, {Thomas R} and Wei Gao and Siegert, {Richard J} and Edmonds, {Polly M} and Schey, {Stephen A} and Higginson, {Irene J}",
year = "2016",
month = "7",
day = "7",
doi = "10.1186/s12885-016-2410-2",
language = "English",
volume = "16",
pages = "427",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma

T2 - a multi-centre study

AU - Ramsenthaler, Christina

AU - Osborne, Thomas R

AU - Gao, Wei

AU - Siegert, Richard J

AU - Edmonds, Polly M

AU - Schey, Stephen A

AU - Higginson, Irene J

PY - 2016/7/7

Y1 - 2016/7/7

N2 - BACKGROUND: Multiple myeloma, the second most common haematological cancer, remains incurable. Its incidence is rising due to population ageing. Despite the impact of the disease and its treatment, not much is known on who is most in need of supportive and palliative care. This study aimed to (a) assess symptom severity, palliative care concerns and health-related quality of life (HRQOL) in patients with multiple myeloma, and (b) to determine which factors are associated with a lower quality of life. We further wanted to know (c) whether general symptom level has a stronger influence on HRQOL than disease characteristics.METHODS: This multi-centre cross-sectional study sampled two cohorts of patients with multiple myeloma from 18 haematological cancer centres in the UK. The Myeloma Patient Outcome Scale (MyPOS) was used to measure symptoms and concerns. Measures of quality of life included the EORTC QLQ-C30, its myeloma module and the EuroQoL EQ-5D. Data were collected on socio-demographic, disease and treatment characteristics and phase of illness. Point prevalence of symptoms and concerns was determined. Multiple regression models quantified relationships between independent factors and the MyPOS, EORTC global quality of life item and EQ5D Index.RESULTS: Five-hundred-fifty-seven patients, on average 3.5 years (SD: 3.4) post-diagnosis, were recruited. 18.2 % had newly diagnosed disease, 47.9 % were in a treatment-free interval and 32.7 % had relapsed/progressive disease phase. Patients reported a mean of 7.2 symptoms (SD: 3.3) out of 15 potential symptoms. The most common symptoms were pain (72 %), fatigue (88 %) and breathlessness (61 %). Those with relapsed/progressive disease reported the highest mean number of symptoms and the highest overall palliative care concerns (F = 9.56, p < 0.001). Factors associated with high palliative care concerns were a general high symptom level, presence of pain, anxiety, low physical function, younger age, and being in the advanced stages of disease.CONCLUSION: Patients with multiple myeloma have a high symptom burden and low HRQOL, in the advanced and the earlier stages of disease. Identification of patients in need of supportive care should focus on assessing patient-reported outcomes such as symptoms and functioning regularly in clinical practice, complementary to traditional biomedical markers.

AB - BACKGROUND: Multiple myeloma, the second most common haematological cancer, remains incurable. Its incidence is rising due to population ageing. Despite the impact of the disease and its treatment, not much is known on who is most in need of supportive and palliative care. This study aimed to (a) assess symptom severity, palliative care concerns and health-related quality of life (HRQOL) in patients with multiple myeloma, and (b) to determine which factors are associated with a lower quality of life. We further wanted to know (c) whether general symptom level has a stronger influence on HRQOL than disease characteristics.METHODS: This multi-centre cross-sectional study sampled two cohorts of patients with multiple myeloma from 18 haematological cancer centres in the UK. The Myeloma Patient Outcome Scale (MyPOS) was used to measure symptoms and concerns. Measures of quality of life included the EORTC QLQ-C30, its myeloma module and the EuroQoL EQ-5D. Data were collected on socio-demographic, disease and treatment characteristics and phase of illness. Point prevalence of symptoms and concerns was determined. Multiple regression models quantified relationships between independent factors and the MyPOS, EORTC global quality of life item and EQ5D Index.RESULTS: Five-hundred-fifty-seven patients, on average 3.5 years (SD: 3.4) post-diagnosis, were recruited. 18.2 % had newly diagnosed disease, 47.9 % were in a treatment-free interval and 32.7 % had relapsed/progressive disease phase. Patients reported a mean of 7.2 symptoms (SD: 3.3) out of 15 potential symptoms. The most common symptoms were pain (72 %), fatigue (88 %) and breathlessness (61 %). Those with relapsed/progressive disease reported the highest mean number of symptoms and the highest overall palliative care concerns (F = 9.56, p < 0.001). Factors associated with high palliative care concerns were a general high symptom level, presence of pain, anxiety, low physical function, younger age, and being in the advanced stages of disease.CONCLUSION: Patients with multiple myeloma have a high symptom burden and low HRQOL, in the advanced and the earlier stages of disease. Identification of patients in need of supportive care should focus on assessing patient-reported outcomes such as symptoms and functioning regularly in clinical practice, complementary to traditional biomedical markers.

U2 - 10.1186/s12885-016-2410-2

DO - 10.1186/s12885-016-2410-2

M3 - Article

C2 - 27387201

VL - 16

SP - 427

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454